$CNBX
CNBX Pharmaceuticals Inc

2023 Q1 Form 10-Q Financial Statement

#000168316823000174 Filed on January 13, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $237.7K $283.9K $670.3K
YoY Change -40.53% -57.65% 196.6%
% of Gross Profit
Research & Development $12.33K $62.89K $440.0K
YoY Change -96.27% -85.71% 1.45%
% of Gross Profit
Depreciation & Amortization $40.39K $43.19K $51.82K
YoY Change -20.16% -16.66% -9.89%
% of Gross Profit
Operating Expenses $250.0K $346.8K $1.110M
YoY Change -65.76% -68.77% 68.3%
Operating Profit -$250.0K -$346.8K -$1.110M
YoY Change -65.76% -68.77%
Interest Expense -$2.374M -$10.88K -$212.7K
YoY Change 366.82% -94.88% -4379.07%
% of Operating Profit
Other Income/Expense, Net $20.99K -$10.88K -$212.7K
YoY Change -104.13% -94.88%
Pretax Income -$2.624M -$357.7K -$1.323M
YoY Change 111.83% -72.97% 102.06%
Income Tax
% Of Pretax Income
Net Earnings -$2.624M -$357.7K -$1.323M
YoY Change 111.83% -72.97% 102.06%
Net Earnings / Revenue
Basic Earnings Per Share -$1.33 -$0.33 -$0.01
Diluted Earnings Per Share -$1.33 -$0.33 -$1.097M
COMMON SHARES
Basic Shares Outstanding 1.258M shares 1.258M shares 131.1M shares
Diluted Shares Outstanding 1.963M shares 1.258M shares 131.1M shares

Balance Sheet

Concept 2023 Q1 2022 Q4 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $47.75K $21.60K $786.4K
YoY Change -79.39% -97.25% 327.33%
Cash & Equivalents $47.75K $21.60K $786.4K
Short-Term Investments
Other Short-Term Assets $61.09K $78.09K $178.2K
YoY Change -63.63% -56.17% 5.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $108.8K $99.69K $964.6K
YoY Change -72.76% -89.67% 173.56%
LONG-TERM ASSETS
Property, Plant & Equipment $353.2K $393.6K $591.6K
YoY Change -34.71% -33.47% -26.63%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $116.2K $564.0K
YoY Change -100.0% -79.39% 4.52%
Other Assets
YoY Change
Total Long-Term Assets $353.2K $509.8K $1.156M
YoY Change -52.15% -55.88% -14.14%
TOTAL ASSETS
Total Short-Term Assets $108.8K $99.69K $964.6K
Total Long-Term Assets $353.2K $509.8K $1.156M
Total Assets $462.1K $609.5K $2.120M
YoY Change -59.39% -71.25% 24.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $710.6K $596.9K $200.5K
YoY Change 199.57% 197.78% -8.49%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $1.539M $1.763M $1.069M
YoY Change 16.18% 65.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.474M $2.584M $1.493M
YoY Change 38.51% 73.09% 237.2%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.474M $2.584M $1.493M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.474M $2.584M $1.493M
YoY Change 38.51% 73.09% 237.2%
SHAREHOLDERS EQUITY
Retained Earnings -$23.53M -$20.91M
YoY Change
Common Stock $222.00 $124.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.012M -$1.974M $627.4K
YoY Change
Total Liabilities & Shareholders Equity $462.1K $609.5K $2.120M
YoY Change -59.39% -71.25% 24.82%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2021 Q4
OPERATING ACTIVITIES
Net Income -$2.624M -$357.7K -$1.323M
YoY Change 111.83% -72.97% 102.06%
Depreciation, Depletion And Amortization $40.39K $43.19K $51.82K
YoY Change -20.16% -16.66% -9.89%
Cash From Operating Activities -$18.53K -$95.92K -$599.6K
YoY Change -96.66% -84.0% 1.17%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$510.00
YoY Change -45.74%
Acquisitions
YoY Change
Other Investing Activities $24.70K $0.00
YoY Change
Cash From Investing Activities $24.70K $0.00 -$510.00
YoY Change -100.0% -45.74%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 19.98K $0.00
YoY Change
NET CHANGE
Cash From Operating Activities -18.53K -$95.92K -599.6K
Cash From Investing Activities 24.70K $0.00 -510.0
Cash From Financing Activities 19.98K $0.00
Net Change In Cash 26.15K -$95.92K -600.1K
YoY Change -104.71% -84.02% 1.09%
FREE CASH FLOW
Cash From Operating Activities -$18.53K -$95.92K -$599.6K
Capital Expenditures $0.00 -$510.00
Free Cash Flow -$18.53K -$599.0K
YoY Change -96.66% 1.24%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001343009
CY2022Q4 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--08-31
CY2022Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q4 dei Document Type
DocumentType
10-Q
CY2022Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q4 dei Document Period End Date
DocumentPeriodEndDate
2022-11-30
CY2022Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q4 dei Entity File Number
EntityFileNumber
000-52403
CY2022Q4 dei Entity Registrant Name
EntityRegistrantName
CNBX PHARMACEUTICALS INC.
CY2022Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5644005
CY2022Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
#3 Bethesda Metro Center
CY2022Q4 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 700
CY2022Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Bethesda
CY2022Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2022Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20814
CY2022Q4 dei City Area Code
CityAreaCode
(877)
CY2022Q4 dei Local Phone Number
LocalPhoneNumber
424-2429
CY2022Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q4 dei Entity Shell Company
EntityShellCompany
false
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1257927 shares
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21600 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117515 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
78085 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
80772 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
99685 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
198287 usd
CY2022Q4 us-gaap Investments
Investments
116217 usd
CY2022Q3 us-gaap Investments
Investments
176087 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
393607 usd
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
436792 usd
CY2022Q4 us-gaap Assets
Assets
609509 usd
CY2022Q3 us-gaap Assets
Assets
811166 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
596913 usd
CY2022Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
461128 usd
CY2022Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1763244 usd
CY2022Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1758702 usd
CY2022Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
223645 usd
CY2022Q3 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
223645 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2583802 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2443475 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1257927 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1257927 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1257927 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1257927 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
124 usd
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
124 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
18107426 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
18031869 usd
CY2022Q4 us-gaap Other Additional Capital
OtherAdditionalCapital
3459510 usd
CY2022Q3 us-gaap Other Additional Capital
OtherAdditionalCapital
3459510 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2634716 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2574846 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20906637 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20548968 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1974293 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1632311 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
609509 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
811166 usd
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62888 usd
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
440044 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
283902 usd
CY2021Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
670305 usd
CY2022Q4 us-gaap Operating Expenses
OperatingExpenses
346790 usd
CY2021Q4 us-gaap Operating Expenses
OperatingExpenses
1110349 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-346790 usd
CY2021Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1110349 usd
CY2022Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10879 usd
CY2021Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-212670 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-357669 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-1323020 usd
CY2022Q4 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-59870 usd
CY2021Q4 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-281211 usd
CY2022Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-417539 usd
CY2021Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1604231 usd
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.33
CY2021Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2021Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1257927 shares
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1257927 shares
CY2021Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131105839 shares
CY2021Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131105839 shares
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-1632311 usd
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
75557 usd
CY2022Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-59870 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-357669 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1974293 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
1805915 usd
CY2021Q4 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
425737 usd
CY2021Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-281211 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-1323020 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
627421 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-357669 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-1323020 usd
CY2022Q4 us-gaap Depreciation
Depreciation
43185 usd
CY2021Q4 us-gaap Depreciation
Depreciation
51823 usd
CY2022Q4 CNBX Convertible Loan Valuation
ConvertibleLoanValuation
4541 usd
CY2021Q4 CNBX Convertible Loan Valuation
ConvertibleLoanValuation
0 usd
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
75557 usd
CY2021Q4 us-gaap Share Based Compensation
ShareBasedCompensation
425737 usd
CY2022Q4 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-2687 usd
CY2021Q4 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-26203 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
135784 usd
CY2021Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
22944 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-95915 usd
CY2021Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-599545 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-95915 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-600058 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117515 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1386472 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21600 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
786414 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-357669 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-20906637 usd
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62888 usd
CY2021Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
440044 usd
CY2022Q4 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zwwxuZnVRPLa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassifications</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
75557 usd
CY2022Q4 us-gaap Accounts Payable Related Parties Current And Noncurrent
AccountsPayableRelatedPartiesCurrentAndNoncurrent
310557 usd
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
900000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 CNBX Monthly Operating Lease Expense
MonthlyOperatingLeaseExpense
6500 usd

Files In Submission

Name View Source Status
0001683168-23-000174-index-headers.html Edgar Link pending
0001683168-23-000174-index.html Edgar Link pending
0001683168-23-000174.txt Edgar Link pending
0001683168-23-000174-xbrl.zip Edgar Link pending
cnbx-20221130.xsd Edgar Link pending
cnbx_ex3101.htm Edgar Link pending
cnbx_ex3102.htm Edgar Link pending
cnbx_ex3201.htm Edgar Link pending
cnbx_ex3202.htm Edgar Link pending
cnbx_i10q-113022.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
image_003.jpg Edgar Link pending
image_004.jpg Edgar Link pending
image_005.jpg Edgar Link pending
image_006.jpg Edgar Link pending
image_007.jpg Edgar Link pending
image_008.jpg Edgar Link pending
image_009.jpg Edgar Link pending
image_010.jpg Edgar Link pending
image_011.jpg Edgar Link pending
image_014.jpg Edgar Link pending
image_015.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cnbx-20221130_cal.xml Edgar Link unprocessable
cnbx-20221130_lab.xml Edgar Link unprocessable
cnbx-20221130_def.xml Edgar Link unprocessable
cnbx-20221130_pre.xml Edgar Link unprocessable
cnbx_i10q-113022_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable